2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

ASCO 2013 - Poster: Preliminary safety, product parameters, and immune response assessments from a phase II, randomized, open-label trial of DN24-02, an autologous cellular immunotherapy, in patients with surgically resected HER+ urothelial cancer at high

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin D,1 Sharma P,2 Lerner S,3 Sims R,4 DeVries T,4 Sheikh N,4 and Gomella LG5 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Complete title: ASCO 2013 - Poster: Preliminary safety, product parameters, and immune response assessments from a phase II, randomized, open-label trial of DN24-02, an autologous cellular immunotherapy, in patients with surgically resected HER+ urothelial cancer at high risk for recurrence

 

asco 2013 NeuACT Poster Bajorin thumb

1Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Baylor College of Medicine, The Scott Department of Urology, Houston, TX, USA; 4Dendreon Corporation, Seattle, WA, USA; 5Jefferson Medical College and Kimmel Cancer Center, Philadelphia, PA, USA 

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x 

View Full ASCO 2013 Coverage